SOMATIC SYMPTOM DISORDERS
Cognitive behavioral therapy has been shown to be an effective treatment for somatoform disorders by reducing physical symptoms, psychological distress, and disability.
Bremelanotide is FDA-approved for the treatment of female hypoactive sexual desire disorder in premenopausal women.
SCHIZOPHRENIA SPECTRUM DISORDERS
There is early evidence that cannabidiol (CBD) is efficacious in improving psychotic symptoms in schizophrenia when added to existing antipsychotic treatment. This may represent a new class of therapy for psychotic disorders.
Allopregnanolone, a neurosteroid allosteric modulator of GABA-a receptors, was approved in 2019 for the treatment of postpartum depression.
OTHER DRUG & SUBSTANCE USE DISORDERS
There is emerging evidence that there is a clinically distinct syndrome associated with vaping tetrahydrocannabinol (THC). Vaping-associated lung injury may result in devastating pulmonary effects and distinct pathophysiology.